U.S. FDA Approves Pfizer’s Xeljanz (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis

NEW YORK–(BUSINESS WIRE) September 28, 2020 — Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Xeljanz® (tofacitinib) for the treatment of children and adolescents 2 years

Setting preschoolers on an active path

(HealthDay)—Physical activity is closely linked to development of a child’s mental skills—ones essential to academic success and navigating challenges they’ll face throughout life. Studies show that boosts in thinking ability, or executive function, often follow